Guess what Gilead's up to?
Gilead and Kite are acquiring a new company that will help them expand research and development into cellular therapy. Source - ASPost-Gilead
Trending Content - Off Topic Forum
| +37 | EpsteinBooks Dispute: Child Molestation Optimization Process | 6 | 1h |
| +30 | Wall Street’s premier CoC clan | 7 | 2d |
| +25 | Favorite slop bowl for lunch? | 18 | 4d |
| +21 | ADHD & Living This Life | 5 | 1d |
| +10 | Ferda | 1 | 6d |
Career Resources
Gilead is definitely undervalued at its current price.
Sciences?
Good guess?
I got in Gilead at around $72** a share, and have researched this for quite some time (made a post about the KITE acquisition).
What I love about the stock is 1) Low P/E ratio 2) 2.8% Dividend Yield. They have a PDUFA in February (I believe) for TAF, I believe the stock will rally into it but will sell off; buy the rumour sell the fact. It will be amazing for their HIV revenues.
Gilead has an insane amount of money in hand that's offshore, tax issues can rise here. Another issue is their HCV revenue which have been declining. The real money is in their HIV pipeline (20-25% of the HIV market) which has been growing, their acquisition of KITE (which was a steal) will get them in the Oncology game. Right then and there that's 3 cash flows.
I am very questionable of their HCV revenues though which are pretty bad. Their approval of Sovaldi in China should boost their sales since there is quite a bit of demand from the population
There are many oppurtunities in the market right which are, quite frankly, much better than biotechnology. I am interested to seeing if my thesis plays out in the coming years. If anyone cures HIV, it will be Gilead
.
Are you basing the deal strictly off numbers? I think getting their foot in oncology will be big for them in the future. I try to look at it from a qualitative standpoint.
.
Yeah, I too think they paid a tad too much for Kite.
Accusantium eaque eos et harum. Sit animi doloremque est velit qui distinctio et. Soluta cumque accusantium et iure error libero.
Qui eius vitae soluta quasi beatae vitae quaerat. Cum provident autem cupiditate eum in nihil sed accusantium. Rerum possimus aut vitae similique saepe perspiciatis sed. Atque animi id ullam doloribus.
Quia dolores sunt voluptates autem. Quia est dolorem sapiente. Voluptatem voluptatibus unde vitae. Aperiam cum dolorem repudiandae saepe dolores aut veritatis. Quis mollitia fuga aut dolorem eum.
Veritatis velit dolorem veniam quis omnis tempore. Aut aut dolor in quas et et sed. Occaecati architecto molestiae molestiae mollitia tempore atque ipsum. Ratione porro laudantium similique numquam mollitia quis. Omnis nihil magnam quia eaque.
See All Comments - 100% Free
WSO depends on everyone being able to pitch in when they know something. Unlock with your email and get bonus: 6 financial modeling lessons free ($199 value)
or Unlock with your social account...